SOHO 2020 | Management of adult T-ALL
Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the management of patients with T-cell acute lymphoblastic leukemia (T-ALL), a rare subtype of ALL, including first-line therapy with chemo-immunotherapy such as nelarabine along with hyper-CVAD. Dr Jain also highlights venetoclax, a BCL-2 inhibitor, as a possible strategy for patients with T-ALL as evaluated in a Phase I study in combination with mini-hyper-CVD. Dr Jain continues to discuss the importance of identifying ETP-ALL patients, a subtype of T-ALL that is associated with higher-risk and requires transplant in first complete remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
